Skip to content
CancerIndex

Publication

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Authors not recorded

Cancer Cell2007PMID 18068628stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (6)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
18068628
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
FLT3 M737I1
(oncogenic)Acute Myeloid LeukemiaCURATED_BROADEROncogenicDDoes Not Support Oncogenicity3accepted
EID12961

FLT3 M737I variant was found in patient at diagnosis but absent in the remission sample. BaF3 cells was transformed to express M737I and these cells were unable to grow in the absence of IL-3 similar … (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

civic
FLT3 V592G1
(oncogenic)Acute Myeloid LeukemiaCURATED_BROADEROncogenicDSupports Oncogenicity3submitted
EID13031

The FLT3 V592G variant was found in a patient with AML. BaF3 cells transformed to express V592G demonstrated proliferation in the absence of IL-3 similar to D835Y positive control. Cell proliferation … (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

civic
FLT3 Y572C4
(oncogenic)Acute Myeloid LeukemiaCURATED_BROADEROncogenicCSupports Oncogenicity1submitted
EID13041

The paper sequenced FLT3 in 222 adult patients with AML and no known FLT3 ITD, KIT, and NRAS mutations. Nine nonsynonmyous changes were identified including one patient with the Y572C amino acid subst… (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

civic
〃Acute Myeloid LeukemiaCURATED_BROADEROncogenicDSupports Oncogenicity5submitted
EID12791

Ba/F3 cell lines engineered to express Y572C showed sustained growth in the absence of IL-3 similar to the D835Y expressing cell line (positive control) (Figure 1A). The Ba/F3 WT expressing cell line… (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

civic
〃Acute Myeloid LeukemiaCURATED_BROADEROncogenicDSupports Oncogenicity4submitted
EID12792

Ba/F3 cell lines engineered to express Y572C showed constitutive phosphorylation of FLT3 (Figure 1B) and phosphorylation of other downstream signaling molecules such as ERK1/2, AKT (Figure 2). Based o… (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

civic
MidostaurinAcute Myeloid LeukemiaCURATED_BROADERPredictiveDSupports Sensitivity Response5submitted
EID12793

Ba/F3 cell lines engineered to express Y572C showed reduced cell growth when exposed to different concentrations of PKC412 (also known as midostaurin )[IC50 (nm) 2.5] (Figure 4A) when compared to a Y5… (full text at CIViC)

PMID 18068628 · Fröhling et al., 2007 · Open in CIViC

civic